Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Dysport Therapeutic abobotulinumtoxinA Upper limb spasticity Reimburse with clinical criteria and/or conditions Complete
Ebglyss lebrikizumab atopic dermatitis Active
Ebixa Memantine hydrochloride Dementia (Alzheimer type), moderate to severe Do not list Complete
Edarbi Azilsartan medoxomil Hypertension Do not list at the submitted price Complete
Edarbyclor Azilsartan medoxomil + chlorthalidone Hypertension Do not list Complete
Edurant Rilpivirine HIV infection List Complete
Effient Prasugrel hydrochloride Acute Coronary Syndrome Do not list Complete
Effient Prasugrel Acute coronary syndrome Do not list Complete
Egrifta Tesamorelin Lipodystrophy, HIV-infected patients Do not reimburse Complete
Elaprase Idursulfase Mucopolysarccharidosis II (MPS II), Hunter Syndrome Do not list Complete